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A Phase 1 and Randomized Controlled Phase 2 Trial of the Safety
and Efficacy of the Combination of Gemcitabine and Docetaxel
With Ontuxizumab (MORAb-004) in Metastatic Soft-Tissue
Sarcomas
1
Robin L. Jones
; Sant P. Chawla2; Steven Attia3; Patrick Schöffski4; Hans Gelderblom5; Bartosz Chmielowski6;
7
Axel Le Cesne ; Brian A. Van Tine8; Jonathan C. Trent9; Shreyaskumar Patel10; Andrew J. Wagner11; Rashmi Chugh12;
15
John W. Heyburn13; Susan C. Weil13; Wenquan Wang13; Kert Viele, PhD14; and Robert G. Maki

BACKGROUND: Ontuxizumab, a humanized monoclonal antibody, targets endosialin (tumor endothelial marker 1 [TEM-1] or CD248),
which is expressed on sarcoma cells and is believed to be involved in tumor angiogenesis. This is the first trial to evaluate ontuxizumab in patients with sarcoma. METHODS: Part 1 was an open-label, dose-finding, safety lead-in: 4, 6, or 8 mg/kg with gemcitabine
and docetaxel (G/D; 900 mg/m2 gemcitabine on days 1 and 8 and 75 mg/m2 docetaxel on day 8). In part 2, patients were randomized
in a double-blind fashion in 2:1 ratio to ontuxizumab (8 mg/kg) or a placebo with G/D. Randomization was stratified by 4 histological
cohorts. RESULTS: In part 2 with 209 patients, no significant difference in progression-free survival between ontuxizumab plus G/D
(4.3 months; 95% confidence interval [CI], 2.7-6.3 months) and the placebo plus G/D (5.6 months; 95% CI, 2.6-8.3 months) was
observed (P = .67; hazard ratio [HR], 1.07; 95% CI, 0.77-1.49). Similarly, there was no significant difference in median overall survival
between the 2 groups: 18.3 months for the ontuxizumab plus G/D group (95% CI, 16.2-21.1 months) and 21.1 months for the placebo
plus G/D group (95% CI, 14.2 months to not reached; P = .32; HR, 1.23; 95% CI, 0.82-1.82). No significant differences between the
treatment groups occurred for any efficacy parameter by sarcoma cohort. The combination of ontuxizumab plus G/D was generally
well tolerated. CONCLUSIONS: Ontuxizumab plus G/D showed no enhanced activity over chemotherapy alone in soft-tissue sarcomas, whereas the safety profile of the combination was consistent with G/D alone. Cancer 2019;125:2445-2454. © 2019 The Authors.
Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the terms of
the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided
the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
KEYWORDS: endosialin, MORAb-004, ontuxizumab, sarcomas, tumor endothelial marker 1 (TEM-1).

INTRODUCTION
Soft-tissue sarcomas are rare solid tumors of mesenchymal origin with more than 50 different histological subtypes, each
with its own underlying biology.1 Despite optimal surgery, approximately 50% of patients will develop metastatic disease.
The outcome of patients with metastatic disease is poor, with a median overall survival (OS) of 12 to 20 months and with few
systemic therapy options.1 Consequently, there is an unmet need for more effective systemic therapies for advanced sarcomas.
Endosialin, or tumor endothelial marker 1 (TEM-1), is a cell surface glycoprotein that is expressed in the stromal
compartment of nearly all human tumors.2 Preclinical studies have shown that endosialin plays a key role in tumor
growth and vessel formation in numerous tumor types, including sarcomas.3,4 Endosialin expression was noted in all
9 sarcoma subtypes and in 83% of all sarcoma specimens.2 Rouleau et al2 demonstrated that endosialin was expressed by
malignant, perivascular, and stromal cells in human specimens. Endosialin expression was found in human specimens
of high-grade/advanced sarcomas.5 Consequently, endosialin was considered a potential therapeutic target in sarcomas.
Other studies confirmed these findings.6
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Ontuxizumab is a humanized immunoglobulin G1κ
antibody directed against endosialin and the first of this
class to undergo clinical evaluation. Nonclinical pharmacological studies have shown that ontuxizumab has
the ability to interfere with specific endosialin receptorligand interactions.7 The combination of gemcitabine
and docetaxel (G/D) is well established in the treatment
of metastatic sarcomas.8 The aim of this trial was to
assess the optimal dose of ontuxizumab in combination
with G/D and to evaluate the ability of the antibody to
enhance the antitumor activity of G/D.
MATERIALS AND METHODS
Patients

Patients older than 18 years with histologically proven
metastatic soft-tissue sarcomas and an Eastern Coopera
tive Oncology Group (ECOG) performance status of
0 to 1 were eligible. In addition, patients had to have measurable disease according to version 1.1 of the Response
Evaluation Criteria in Solid Tumors (RECIST), to have
been treated with 0 to 2 prior lines of systemic therapy,
and to have fully recovered from all toxicities of previous treatments (apart from alopecia). Patients had to have
adequate hematologic, renal, and liver parameters and no
brain metastases, primary bone sarcomas, other active
malignancies, or an uncontrolled medical condition.
Before enrollment was commenced, local institutional review board/ethics committee approval was obtained in accordance with the Declaration of Helsinki.
Investigators obtained informed consent from each
participant.
Study Design and Treatment

This was a multicenter, sequential, 2-part trial. Part 1
was an open-label, dose-escalation design used to establish the safety of ontuxizumab combined with G/D
and to define the recommended phase 2 dose. The doseescalation phase consisted of ontuxizumab (days 1 and
8 of a 21-day cycle) in combination with gemcitabine at
900 mg/m2 (days 1 and 8) and docetaxel at 75 mg/m2
(day 8).
The recommended phase 2 dose was defined as the
highest ontuxizumab dose administered in combination
with G/D at which 0 of 3 patients or no more than 1
of a maximum of 6 patients in a given dose cohort experienced a dose-limiting toxicity (DLT). Patients were
treated until disease progression. A DLT was defined as
treatment-related and occurring within the first 28 days
of treatment. DLTs included 1) a nonhematologic
2446

toxicity of grade 3 or higher (excluding grade 3 asthenia unless lasting longer than 3 days, nausea/vomiting
unless optimally treated, and alopecia); 2) a hematologic toxicity of grade 4 neutropenia lasting longer than 7 days, grade 4 febrile neutropenia, a grade
3/4 infection with associated grade 3/4 neutropenia,
a grade 4 hematologic toxicity not resolving in fewer
than 14 days, or grade 3 thrombocytopenia with clinically significant bleeding; 3) delayed recovery causing a delay of the next dose longer than 28 days; and
4) an infusion-related toxicity excluding those controlled to grade 2 or lower by management and anaphylactic reactions.
Part 2 was a randomized, double-blind, placebocontrolled trial of G/D with either 8 mg/kg ontuxizumab
or a placebo and used the same doses and schedule used
in part 1. Patients were randomly assigned in a 2:1 ratio
to ontuxizumab plus G/D or the placebo plus G/D and
were stratified into 4 sarcoma cohorts.
Study Assessments

The response to treatment was determined by computed
tomography or magnetic resonance imaging performed
at screening and every 6 weeks for the first 24 ± 1 weeks
and then every 12 weeks. Patients who discontinued the
study drug were followed for documentation of disease
progression, any additional anticancer therapies, and
survival.
The primary endpoint for part 2 was progressionfree survival (PFS). Secondary endpoints included OS,
the overall response rate based on RECIST 1.1, safety,
and tolerability. Exploratory objectives included the evaluation of putative predictive markers of response.
Safety was evaluated by the monitoring of adverse
events (AEs; graded via Common Toxicity Criteria for
Adverse Events, version 4.03), serious adverse events (SAEs),
laboratory measurements, vital signs, electrocardiograms,
ECOG assessments, and physical examinations.
Biomarkers, Antidrug Antibody,
and Pharmacokinetic Analysis

Tumor tissue was obtained from all patients from an initial diagnostic tissue sample or an optional biopsy during screening or previous treatment. Formalin-fixed,
paraffin-embedded slides underwent immunohistochemistry for endosialin and platelet-derived growth
factor receptor β (PDGFR-β), as previously described,7,9
with endosialin antibody clone 9G5 (Morphotek,
Exton, Pennsylvania) and PDGFR-β antibody 28E1
(Cell Signaling Technology, Danvers, Massachusetts).
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Immunohistochemistry was validated and performed
by PhenoPath Laboratories (Seattle, Washington). The
tumor content of slides was reviewed, and tissues controls
were incorporated into each run.
Slides were evaluated by a board-certified pathologist as percentages of cells with expression at intensities of
0 (negative), 1+ (weak), 2+ (moderate), and 3+ (strong).
The level of biomarker expression in each subcompartment was assessed as the M score, which was calculated
as [(% of population scoring 1+) + (2 × % of population
scoring 2+) + (3 × % of population scoring 3+)]/6.
Baseline serum biomarkers were assayed to quantitate the levels of endosialin and PDGFR-β as previously
described.10 The detection of the ontuxizumab antidrug
antibody in serum samples was performed as previously
described.11 Serum concentrations of ontuxizumab
were measured at each cycle for pharmacokinetic analysis. Ontuxizumab concentrations were measured with
an 
endosialin antigen–based electrochemiluminescent
immunoassay to capture and quantify the serum concentration of free/partially complexed ontuxizumab.11
Statistics

Parts 1 and 2 of the study were summarized and analyzed
separately. The sample size was planned to be a maximum of 19 patients for part 1 and 225 patients for part
2 (120-200 patients in part 2, with a particular sarcoma
cohort to have no more than 60 patients). An independent, unblinded committee monitored the trial. Part 1
data were summarized descriptively by dose level.
In part 2, the primary analysis of PFS was conducted at the time at which 185 PFS events (progression or death) were observed; Kaplan-Meier curves were
used, with 95% confidence intervals (CIs) for medians
calculated according to Brookmeyer and Crowley.12 PFS
in treatment groups was compared in the intent-to-treat
population on the basis of the log-rank test, and the hazard ratio (HR) was estimated on the basis of the Cox
proportional hazards model. These analyses were also
conducted separately by sarcoma cohort. OS was summarized in a similar manner.
The overall response rate (complete or partial) was
summarized with 95% CIs with the Clopper-Pearson
exact binomial CI13 for each treatment group. To identify
differences between treatment groups overall and within
sarcoma cohorts, a Bayesian hierarchical model was used
to model PFS across the 4 strata.14 Safety data were summarized with descriptive statistics.
Cox regression modeling was used to assess the
influence of baseline tissue and serum biomarkers as
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covariates on PFS and OS. If the univariate regression
model P value (with the Wald chi-square test) for the factor was <.2, then the factor was included as a candidate
for inclusion in a stepwise selection process using a multivariate Cox regression model. Interactions between treatment and each factor were explored to assess each factor’s
ability to predict a clinical response. Exposure-response
relations were evaluated with Kaplan-Meier curves and
were characterized in terms of median PFS and OS with
2-sided 95% CIs constructed with the methodology of
Brookmeyer and Crowley.12
RESULTS
Part 1

Sixteen patients enrolled in part 1. Two dose levels of
ontuxizumab (4 and 8 mg/kg) were planned in combination with G/D. No DLTs were observed in the 3 p
 atients
treated within cohort 1 (ontuxizumab at 4 mg/kg).
One of the 6 patients in cohort 2 (ontuxizumab at
8 mg/kg) experienced grade 4 febrile neutropenia. An
additional patient in cohort 2 experienced a non-DLT
event of grade 4 neutropenia. Both patients in cohort
2 had previously received more than 6 months of combination chemotherapy. Therefore, the G/D reduction
criterion was amended to require a decrease of 25% of
the starting dose for G/D for those previously treated
with more than 6 months of combination chemotherapy. With this new criterion, 2 further de-escalation
dose cohorts (cohorts 3 and 4) were opened. In cohort 3,
the dose was decreased to 6 mg/kg, and no DLTs were
observed. Therefore, the dose was re-escalated to 8 mg/kg
in cohort 4, and no additional DLTs were observed.
In total, 3 patients received 4 mg/kg ontuxizumab,
4 patients received 6 mg/kg ontuxizumab, and 9 patients
received 8 mg/kg ontuxizumab. The recommended
phase 2 dose of ontuxizumab in combination with G/D
was 8 mg/kg. There were no treatment-related deaths or
SAEs, and there were no AEs resulting in discontinuation from the trial in part 1.
Part 2

A total of 255 patients were screened for entry into part 2,
and 209 were randomized. Among the 46 screen failures,
2 patients (0.8%) did not have measurable disease by
RECIST 1.1, 1 patient (0.4%) failed to meet inclusion/
exclusion criteria, and 43 patients (16.9%) were excluded
for other reasons.
Patients were enrolled at 31 sites in the United
States, Australia, and Europe and randomized to either
2447
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TABLE 1. Baseline Characteristics for Patients Enrolled in Part 2 (Intent-To-Treat Population)
Ontuxizumab at 8 mg/kg + G/D (n = 139)

Placebo + G/D (n = 70)

55 (13)

54 (14)

55 (14)

76 (55)
63 (45)

38 (54)
32 (46)

114 (55)
95 (46)

116 (83)
12 (9)
11 (8)

57 (81)
9 (13)
4 (6)

173 (83)
21 (10)
15 (7)

3 (2)
21 (15)
82 (59)
22 (16)
11 (8)

4 (6)
13 (19)
38 (54)
9 (13)
6 (9)

7 (3)
34 (16)
120 (57)
31 (15)
17 (8)

67 (48)
72 (52)
74 (53)
65 (47)
53 (38)
21 (15)

39 (56)
31 (44)
40 (57)
30 (43)
29 (41)
11 (16)

106 (51)
103 (49)
114 (55)
95 (45)
82 (39)
32 (15)

30 (22)
41 (29)
30 (22)

15 (21)
21 (30)
15 (21)

45 (22)
62 (30)
45 (22)

38 (27)
3
3
6
14
12

19 (27)
2
2
1
6
8

57 (27)
5
5
7
20
20

Age, mean (SD), y
Sex, No. (%)
Male
Female
Race, No. (%)
White
Black or African American
Other
Initial histologic diagnosis grade, No. (%)
1
2
3
Unknown
Missing
Baseline ECOG performance status, No. (%)
0
1
Prior chemotherapy in the metastatic setting
First line
Second line
Third line
Histologic subtype, No. (%)
Liposarcoma
Leiomyosarcoma
Undifferentiated pleomorphic sarcoma
or myxofibrosarcoma
Other
Angiosarcoma
Spindle cell sarcoma
Peripheral nerve sheath tumor
Synovial sarcoma
Miscellaneous or unclassifieda

Total (n = 209)

Abbreviations: ECOG, Eastern Cooperative Oncology Group; G/D, gemcitabine and docetaxel; SD, standard deviation.
a
The miscellaneous and unclassified histologic subtypes included patients with histologic diagnoses of rhabdomyosarcoma (3), unclassified sarcoma (3), epithelioid sarcoma (3), hemangiopericytoma (2), endometrial sarcoma (2), adenosarcoma (1), clear cell sarcoma (1), fibrosarcoma (1), intimal sarcoma (1), phyllodes (1), other liposarcoma (1), and small blue round cell tumor (1).

ontuxizumab plus G/D (139 patients) or the placebo
plus G/D (70 patients) and were included in the intentto-treat population.
Of the 209 randomized patients, 2 in the ontuxizumab plus G/D arm discontinued the trial before dosing, 1 because of death from progressive disease and 1
because of complications of hypertension. A total of 207
patients received at least 1 dose of ontuxizumab plus
G/D or the placebo plus G/D, and 204 of these patients
(98.6%) discontinued the trial.
The baseline disease characteristics are displayed
in Table 1. The study population consisted of 114
males (55%), and the median age was 56 years (range,
21-81 years). The proportion of patients with a baseline
ECOG score of 1 was higher in the ontuxizumab plus
G/D group (72 of 139 patients or 52%) than the placebo
plus G/D group (31 of 70 patients or 44%).
The duration of treatment for the ontuxizumab
plus G/D group was a mean of 5.1 months (range, 0.321.4 months) with a mean relative dose intensity of 97%.
2448

The duration of treatment for the placebo plus G/D
group was 5.4 months (range, 0.3-21.2 months) with a
mean relative dose intensity of 99.9%. Treatment delays
associated with an AE occurred in 42% of the patients
receiving ontuxizumab plus G/D and in 45% of the
patients receiving the placebo plus G/D. Dose reductions
occurred in 8% of the patients in both arms.
There was no significant difference between treatment arms for PFS. The median PFS was 4.3 months
(95% CI, 2.7-6.3 months) in the ontuxizumab plus G/D
arm and 5.6 months (95% CI, 2.6-8.3 months) in the
placebo plus G/D arm (P = .67; HR, 1.07; 95% CI, 0.771.49). The Kaplan-Meier curves for PFS are displayed in
Figure 1. No significant difference between treatment
arms was apparent by sarcoma cohort (Table 2).
There was no significant difference in median
OS between the 2 arms: 18.3 months (95% CI, 16.221.1 months) in the ontuxizumab plus G/D arm and
21.1 months (95% CI, 14.2 months to not reached) in
the placebo plus G/D arm (P = .32; HR, 1.23; 95%
Cancer  

July 15, 2019

Ontuxizumab in Metastatic Soft-Tissue Sarcomas/Jones et al

Figure 1. Kaplan-Meier curves of progression-free survival for all sarcoma subtypes in part 2 (intent-to-treat population).
CI indicates confidence interval; G/D, gemcitabine and docetaxel.

CI, 0.82-1.83). The Kaplan-Meier curves for OS are
displayed in Figure 2.
The only sarcoma cohort with a longer median
PFS in the ontuxizumab group was the “other” cohort.
The other cohort comprised at least 13 different histological subtypes and included angiosarcomas (n = 5),
spindle cell sarcomas (n = 5), peripheral nerve sheath
tumors (n = 7), synovial sarcomas (n = 20), and miscellaneous types (n = 20). Patients with spindle cell sarcoma
treated with ontuxizumab had longer median PFS and
OS than patients treated with the placebo (median PFS,
2.8 months with ontuxizumab and 1.6 months with the
placebo; median OS, 10.7 months with ontuxizumab
and 2.0 months with the placebo). Patients treated with
ontuxizumab in the miscellaneous subcategory also had
longer median PFS and OS than patients treated with the
placebo. These were exploratory analyses, and no statistical comparisons were made.
There was no significant difference in the overall response rate between the 2 arms (P = 1.00) or by
sarcoma cohort (P < .2 for HR <0.75). Three patients
achieved a complete response: 1 (1%) was treated with
ontuxizumab plus G/D, and 2 (3%) were treated with
Cancer  
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the placebo plus G/D. A partial response was achieved
by 38 patients: 26 (19%) were treated with ontuxizumab
plus G/D, and 12 (17%) were treated with the placebo
plus G/D. Sixty patients (43%) in the ontuxizumab plus
G/D arm and 33 patients (47%) in the placebo plus
G/D arm had stable disease as their best response.
At trial termination, 2 patients with partial responses
continued ontuxizumab. Both patients achieved a partial
response at cycle 17 that continued for more than 2 years
on therapy.
Safety

All patients in the ontuxizumab plus G/D arm and
the placebo plus G/D arm had at least 1 treatment-
emergent AE; the most common (in ≥40% of all
patients) were fatigue (74% vs 66%), anemia (61% vs
60%), nausea (56% vs 52%), diarrhea (44% vs 36%),
peripheral edema (42% vs 45%), and thrombocytopenia (41% vs 43%) respectively.
A numerically higher proportion of patients in the
ontuxizumab plus G/D group (86%) versus the placebo
plus G/D group (76%) had treatment-emergent AEs
that were considered related to the treatment (Table 3).
2449
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TABLE 2. PFS With the Bayesian Hierarchical
Model in Part 2
Sarcoma Type
Liposarcoma
No.
PFS observed, median, wk
Hazard ratio (95% CI)
OS observed, median, wk
Hazard ratio (95% CI)
BOR (% with response)
P
Leiomyosarcoma
No.
PFS observed, median, wk
Hazard ratio (95% CI)
OS observed, median, wk
Hazard ratio (95% CI)
BOR (% with response)
P
UPS
No.
PFS observed, median, wk
Hazard ratio (95% CI)
OS observed, median, wk
Hazard ratio (95% CI)
BOR (% with response)
P
Other
No.
PFS observed, median, wk
Hazard ratio (95% CI)
OS observed, median, wk
Hazard ratio (95% CI)
BOR (% with response)
P

Ontuxizumab at
8.0 mg/kg + G/D

Placebo + G/D

30
14.6

15
24.1
1.12 (0.69-1.89)

58.5

54.4
1.1 (0.56-1.87)
20/30 (67)
12/15 (80)
.236
41
18.3

21
24.0
1.08 (0.68-1.61)

64.6

69.1
1.3 (0.74-2.28)
27/41 (66)
16/21 (76)
.551
30
10.3

15
33.6
1.23 (0.73-2.09)

54.1

55.3
1.2 (0.68-2.00)
16/30 (53)
11/15 (73)
.174
38
10.3

19
6.7
1.01 (0.60-1.54)

56.6

57.1
1.1 (0.63-1.70)
24/38 (63)
8/19 (42)
.389

Abbreviations: BOR, best overall response (stable disease, partial response, or complete response); CI, confidence interval; G/D, gemcitabine
and docetaxel; OS, overall survival; PFS, progression-free survival; UPS,
undifferentiated pleomorphic sarcoma.

Treatment-related AEs that occurred in a higher proportion of patients (>10% difference) in the ontuxizumab
plus G/D arm than the placebo plus G/D arm included
fatigue, headache, pyrexia, diarrhea, and vomiting. Rash
occurred more frequently in the placebo plus G/D arm
(18 of 67 or 27%) than the ontuxizumab plus G/D arm
(16 of 140 or 11%).
The frequencies of patients with at least 1 SAE were
similar in the 2 arms: 50% in the ontuxizumab plus G/D
arm and 48% in the placebo plus G/D arm. The most
frequent treatment-related SAEs were pyrexia (3% overall, 4% in the ontuxizumab plus G/D arm, and 0% in
the placebo plus G/D arm) and anemia (2% overall, 1%
in the ontuxizumab plus G/D arm, and 3% in the placebo plus G/D arm). There were no differences in laboratory values, vital signs, or electrocardiogram parameters
between the 2 arms.
One patient in each arm died of a treatment-
related AE (cardiac arrest in the ontuxizumab plus
2450

G/D arm and respiratory failure in the placebo plus
G/D arm arm). Two patients (1%) in the ontuxizumab
plus G/D arm experienced drug hypersensitivity AEs
(infusion-related reaction and pyrexia/flushing); all
were nonserious and grade 1. None of the drug hypersensitivity AEs resulted in an interruption or discontinuation of ontuxizumab. One patient on ontuxizumab
plus G/D developed a transient treatment-induced
a ntidrug antibody response.
Biomarkers and Pharmacokinetics

Baseline tumor tissue expression of endosialin and
PDGFR-β were measured in the subcompartments of
arterial endothelial, capillary endothelial, cytoplasmic
tumor endothelial, lymphatic endothelial, membranous
tumor endothelial, nonvascular stromal, perivascular,
and venous endothelial cells (Table 4). No significant
difference in baseline biomarker expression between
arms was observed. The highest levels of endosialin
were measured in nonvascular stromal, perivascular, and venous endothelial cells. The highest levels
of PDGFR-β were measured in capillary endothelial,
c ytoplasmic tumor, lymphatic endothelial, nonvascular
stromal, and perivascular cells.
A prognostic biomarker demonstrates an association
with outcome, regardless of therapy. Factors considered
possibly prognostic of PFS included the log serum endosialin concentration (P = .06), tissue endosialin in venous
endothelial cells (P = .04), and tissue PDGFR-β in capillary endothelial cells (P = .10). Longer PFS was associated
with higher serum endosialin concentrations (HR, 0.61;
95% CI, 0.36-1.03), lower tissue endosialin expression in
venous endothelial cells (HR, 1.01; 95% CI, 1.0-1.02),
and lower tissue PDGFR-β levels in capillary endothelial
cells (HR, 0.74; 95% CI, 0.51-1.06). Factors considered
possibly prognostic of OS were endosialin cytoplasmic
tumor endothelial cells (P = .09) and endosialin membranous tumor endothelial cells (P = .12). Longer OS
was associated with lower tissue endosialin levels in
cytoplasmic tumor endothelial cells (HR, 1.01; 95%
CI, 1.0-1.02) and higher tissue endosialin expression in
membranous tumor endothelial cells (HR, 1.02; 95%
CI, 1.0-1.04).
A predictive biomarker provides information
about the effect of a therapeutic intervention on clinical outcomes and can potentially be used to select
patients for therapy. Tissue PDGFR-β in capillary
endothelial cells showed a significant treatment interaction (P = .02), with values below the median associated
with improved PFS (HR, 0.55, 95% CI, 0.29-1.04). No
Cancer  
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Figure 2. Kaplan-Meier curves of overall survival for all sarcoma subtypes in part 2 (intent-to-treat population). CI indicates
confidence interval; G/D, gemcitabine and docetaxel.

TABLE 3. Treatment-Emergent Adverse Events Considered Related to the Treatment by the Investigator in
≥15% of Patients in Either Treatment Group in Part 2 (Safety Population)
Preferred Terma

Ontuxizumab at 8 mg/kg + G/D (n = 140), No. (%)

Fatigue
Nausea
Headache
Anemia
Pyrexia
Diarrhea
Thrombocytopenia
Edema, peripheral
Decreased appetite
Myalgia
Vomiting
Chills
Rash

Placebo + G/D (n = 67), No. (%)

66 (47)
44 (31)
42 (30)
39 (28)
35 (25)
31 (22)
29 (21)
28 (20)
28 (20)
25 (18)
24 (17)
21 (15)
16 (11)

23 (34)
15 (22)
9 (13)
18 (27)
8 (12)
6 (9)
11 (16)
13 (19)
10 (15)
5 (8)
3 (4)
3 (5)
18 (27)

Total (n = 207), No. (%)
89 (43)
59 (29)
51 (25)
57 (28)
43 (21)
37 (18)
40 (19)
41 (20)
38 (18)
30 (15)
27 (13)
24 (12)
34 (16)

Abbreviation: G/D, gemcitabine and docetaxel.
a
Adverse events were coded with the Medical Dictionary for Drug Regulatory Activities, version 14.1.

baseline biomarkers were predictive of improved OS
with ontuxizumab.
Ontuxizumab had no clear exposure effect on PFS
or OS.
DISCUSSION
Ontuxizumab in combination with G/D was well tolerated in patients with soft-tissue sarcomas. Despite
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promising preclinical data and some durable benefit in
patients with sarcoma treated within phase 1 trials,11 the
combination did not show superior activity in comparison with G/D alone in this randomized trial. This was
consistent in all 4 histological cohorts studied in the randomized component of the trial.
The G/D combination was used in this study
because it has proven efficacy in advanced sarcomas.8,15,16
2451

Original Article
TABLE 4. Mean Baseline Biomarker Values for Patients Enrolled in Part 2 (Intent-To-Treat Population)
Biomarker

Ontuxizumab at 8 mg/kg + G/D (n = 139)

Endosialin lymphatic endothelial cell M score
Endosialin membranous tumor cell M score
Endosialin nonvascular stromal cell M score
Endosialin perivascular cell M score
Endosialin venous endothelial cell M score
Log plasma endosialin, ng/mL
PDGFR-β arterial endothelial cell M score
PDGFR-β capillary endothelial cell M score
PDGFR-β cytoplasmic tumor cell M score
PDGFR-β lymphatic endothelial cell M score
PDGFR-β membranous tumor cell M score
PDGFR-β nonvascular stromal cell M score
PDGFR-β perivascular cell M score
PDGFR-β venous endothelial cell M score
Log plasma PDGFR-β, ng/mL

12.8
4.2
18.3
24.1
19.1
11.463
3.4
30.0
22.7
22.0
8.3
21.4
31.8
3.6
7.830

Placebo + G/D (n = 70)
13.3
4.3
18.7
22.9
16.8
11.486
3.2
29.0
21.5
21.7
4.7
23.4
29.8
3.5
7.872

Abbreviations: G/D, gemcitabine and docetaxel; PDGFR-β, platelet-derived growth factor receptor β.

A previous trial reporting a median PFS of 7.5 months with
G/D and bevacizumab17 provided support for the combination of G/D with antiangiogenic agents in sarcomas.
Ontuxizumab was used in this trial to evaluate the hypothesis that blocking endosialin-mediated
tumor angiogenesis would enhance the efficacy of G/D
in sarcomas. However, no improvement in PFS or OS
was observed with ontuxizumab. A major difficulty in
conducting trials for sarcomas is the profound heterogeneity of these diseases. One of the goals of this trial
was to evaluate the benefit of ontuxizumab in all soft-
tissue sarcomas as well as specific cohorts to potentially
identify subsets that might benefit from ontuxizumab.
Ontuxizumab showed no additional benefit in liposarcoma, leiomyosarcoma, or undifferentiated pleomorphic
sarcoma. However, in the heterogeneous “other” cohort,
longer median PFS (not statistically significant) was
observed with ontuxizumab. To evaluate potential benefits in specific subtypes included in the other cohort,
we performed an exploratory analysis. The spindle cell
and miscellaneous sarcoma subcategories showed a nonsignificantly but numerically longer median PFS with
ontuxizumab treatment.
The choice of the ontuxizumab dose in this trial
was based on the completed phase 1 trial of single-agent
ontuxizumab with a maximum tolerated dose of
12 mg/kg.11 One potential criticism of our trial is that the
dose of ontuxizumab was not high enough. In the phase
1 study, pharmacokinetic data suggested an accumulation
of ontuxizumab at 4 mg/kg, and exposures were similar
between 8 and 12 mg/kg with weekly administration. For
this reason, the decision was made a priori not to go above
8 mg/kg ontuxizumab in combination with G/D for the
current trial. Because of the potential accumulation of
2452

ontuxizumab at doses higher than 4 mg/kg, we may not
have given a high enough dose of ontuxizumab. However,
pharmacokinetic analyses indicated that ontuxizumab exposure had no effect on PFS or OS.
The profile of AEs occurring more frequently in
the ontuxizumab arm (fatigue, headache, pyrexia, diarrhea, and vomiting) resembles the profile of the most
frequent AEs observed in the phase 1 trial.11 These results suggest that ontuxizumab did have a pharmacological effect in the current trial. Whether this dose
was sufficiently high to block the angiogenic effect of
endosialin is not certain.
Endosialin is believed to increase the proliferation
of pericytes and result in enhanced tumor angiogenesis
via a platelet-derived growth factor receptor signaling
pathway.3 In the current trial, patients were not selected
on the basis of endosialin expression.
A longer PFS was associated with a higher serum
endosialin concentration, a lower tissue endosialin
expression in venous endothelial cells, and a lower

tissue PDGFR-β level in capillary endothelial cells at
the baseline. Among ontuxizumab-treated patients, a
lower tissue PDGFR-β expression in capillary endothelial cells was associated with improved PFS, and this
indicated that it was a potential predictive indicator of
improved PFS with ontuxizumab.
Although compelling evidence linked the expression of endosialin with tumor growth and progression
in preclinical studies, the biomarkers measured in this
trial showed no predictive association with outcome in
the ontuxizumab plus G/D arm. One potential reason
for the weak association between endosialin-associated
biomarkers and outcome is the low efficacy of ontuxizumab in this trial.
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On the basis of these data, further trials of
ontuxizumab for soft-tissue sarcomas are not warranted.
Because of the stratification by subtype, this trial provides a benchmark of the subtype-specific efficacy of
G/D. In the future, the potential use of antibody-drug
conjugates to selectively deliver cytotoxic agents to tumor
sites could be evaluated. Because endosialin is highly
expressed in sarcomas,2,5 ontuxizumab could be used to
target sarcoma cells and deliver cytotoxic agents linked
to it. In a human endosialin-positive sarcoma xenograft
model, prolonged antitumor activity of an anti-endosialin
antibody conjugated to cytotoxic agents was observed in
comparison with controls.18
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